Cyclin-dependent kinases (CDKs) are pivotal mediators and effectors of the DNA damage
response (DDR) that regulate both the pathway components and proteins involved in repair …

Background Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal cancers, is
driven by oncogenic KRAS mutations. Farnesyl thiosalicylic acid (FTS), also known as …

Simple Summary Prostate cancer continues to exert a significant public health burden
across the globe with hundreds of thousands of new diagnoses per year. There have been …

Occurrence of resistance to olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor
(PARPi) approved in ovarian carcinoma, has already been shown in clinical settings …

Cholangiocarcinoma (CCA) is a poorly treatable type of cancer and its incidence is
dramatically increasing. The lack of understanding of the biology of this tumor has slowed …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, and
survival rates have barely improved in decades. In the era of precision medicine, treatment …

Cancer is the second leading cause of death in the world, and chemotherapy is one of the
main methods of cancer treatment. However, the resistance of cancer cells to …

Ovarian cancer (OC) is the seventh most common type of cancer in women worldwide.
Treatment for OC usually involves a combination of surgery and chemotherapy with …

Although the role of senescence in many physiological and pathological processes is
becoming more identifiable, many aspects of senescence are still enigmatic. A special …

Simple Summary PARP inhibitors (PARPi) have broad applicability as monotherapy in
tumors with HR defects. However, their combination with radiotherapy (RT) is less advanced …